Immunotherapy for Solid Tumours
Immune checkpoint inhibitor evaluation, protocol selection, administration, and immune-related adverse event monitoring by Dr. Kunal Jain.
Immunotherapy Care for Solid Tumours
Immunotherapy works by empowering the body's own immune system to recognize and attack cancer cells. Unlike traditional cytotoxic chemotherapy, immune checkpoint inhibitors target immune regulatory pathways that tumours use to evade destruction.
As a consultant in Medical Oncology trained at GCRI Ahmedabad, Dr. Kunal Jain evaluates solid tumour patients for immunotherapy eligibility based on biomarker status, staging, and clinical guidelines.
Immunotherapy Clinical Protocols
- Patient & Biomarker Selection: Reviewing pathology and biomarker markers (such as PD-L1 Expression / MSI-H) to determine immunotherapy suitability.
- Solid Tumour Protocols: Administering checkpoint inhibitor infusions for eligible solid tumours including lung, renal, bladder, melanoma, and head & neck cancers.
- Infusion Management: Executing infusions under controlled day-care oncology settings with pre-medication and monitoring.
- Immune-Mediated Adverse Event Management: Close surveillance for immune-related adverse events (irAEs) affecting thyroid, lungs, gut, or skin.
- Combination Strategy Review: Evaluating chemotherapy-immunotherapy combination regimens when clinically indicated.
Focused Clinical Precision
Immunotherapy protocols require specialized expertise to distinguish between true disease response, pseudoprogression, and immune-mediated side effects. Dr. Jain personally monitors each patient throughout treatment cycles.
Book a Consultation
Fill out the form below for an in-person or online oncology consultation with Dr. Kunal Jain.